journal article·2022-07-27Open access

Genetically Engineered Nanoparticles of Asymmetric Triblock Polypeptide with a Platinum(IV) Cargo Outperforms a Platinum(II) Analog and Free Drug in a Murine Cancer Model

Soumen Saha, Samagya Banskota, Jianqiao Liu, Nikita Zakharov, Michael Dzuricky, Xinghai Li, Ping Fan, Sonal Deshpande, Ivan Spasojevic, Kedar Sharma, Mario Juan Borgnia, Jeffrey L. Schaal, Ashutosh Raman, Sarah Kim, Jayanta Bhattacharyya, Ashutosh Chilkoti

Nano Letters· Volume 22· Issue 14

Abstract

The development of platinum(Pt)-drugs for cancer therapy has stalled, as no new Pt-drugs have been approved in over a decade. Packaging small molecule drugs into nanoparticles is a way to enhance their therapeutic efficacy. To date, there has been no direct comparison of relative merits of the choice of Pt oxidation state in the same nanoparticle system that would allow its optimal design. To address this lacuna, we designed a recombinant asymmetric triblock polypeptide (ATBP) that self-assembles into rod-shaped micelles and chelates Pt(II) or enables covalent conjugation of Pt(IV) with similar morphology and stability. Both ATBP-Pt(II) and ATBP-Pt(IV) nanoparticles enhanced the half-life of Pt by ∼45-fold, but ATBP-Pt(IV) had superior tumor regression efficacy compared to ATBP-Pt(II) and cisplatin. These results suggest loading Pt(IV) into genetically engineered nanoparticles may yield a new generation of more effective platinum-drug nanoformulations.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States

Duke University School of Medicine, Department of Medicine Oncology and Duke Cancer Institute PK/PD Core Laboratory, Durham, North Carolina 27710, United States

Molecular Microscopy Consortium, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, United States

Funding

National Institute of General Medical Sciences · Dr. Reddy?s laboratory

References (46)

Show source-provided references
1. 10.1039/C6DT01738J10.1039/C6DT01738J ↗
2. 10.1021/acs.chemrev.5b0059710.1021/acs.chemrev.5b00597 ↗
3. National Institutes of Health Clinical Trials Database https://www.clinicaltrials.gov/ct2/results?cond=Cancer&term=&cntry=&state=&city=&dist= (accessed Jun 28, 2021).
4. 10.1093/jnci/djk19610.1093/jnci/djk196 ↗
5. 10.1016/j.addr.2013.09.01410.1016/j.addr.2013.09.014 ↗
6. 10.1080/17425247.2017.130733810.1080/17425247.2017.1307338 ↗
7. 10.1007/s00280-016-2976-z10.1007/s00280-016-2976-z ↗
8. 10.1038/163723b010.1038/163723b0 ↗
9. 10.1002/cmdc.20060027910.1002/cmdc.200600279 ↗
10. 10.1021/cc030011z10.1021/cc030011z ↗
11. 10.1016/S0022-2275(20)37226-610.1016/S0022-2275(20)37226-6 ↗
12. 10.1016/0065-2571(87)90004-510.1016/0065-2571(87)90004-5 ↗
13. 10.1002/chem.20050101210.1002/chem.200501012 ↗
14. 10.2174/18715200777931408010.2174/187152007779314080 ↗
15. Anderson W. K. · Cancer Treat. Rep. · 1986 · 70 · 997
16. 10.1016/j.biomaterials.2011.06.07210.1016/j.biomaterials.2011.06.072 ↗
17. 10.1158/0008-5472.CAN-05-400710.1158/0008-5472.CAN-05-4007 ↗
18. 10.1021/la980572l10.1021/la980572l ↗
19. 10.1021/acs.nanolett.8b0355810.1021/acs.nanolett.8b03558 ↗
20. 10.1021/acs.nanolett.9b0509410.1021/acs.nanolett.9b05094 ↗
21. Nishiyama N. · Cancer Res. · 2003 · 63 · 8977
22. 10.1073/pnas.080915410510.1073/pnas.0809154105 ↗
23. 10.1080/106118602100007245610.1080/1061186021000072456 ↗
24. 10.1021/ja907128210.1021/ja9071282 ↗
25. 10.1517/1354378090311416810.1517/13543780903114168 ↗
26. Stathopoulos G. P. · Anticancer Res. · 2006 · 26 · 1489
27. 10.1007/s00280-006-0235-410.1007/s00280-006-0235-4 ↗
28. 10.1002/adtp.20190016410.1002/adtp.201900164 ↗
29. 10.1038/nmat256910.1038/nmat2569 ↗
30. 10.1002/adfm.20160542110.1002/adfm.201605421 ↗
31. 10.1042/bj199003110.1042/bj1990031 ↗
32. 10.1007/978-1-60327-198-1_610.1007/978-1-60327-198-1_6 ↗
33. 10.1073/pnas.120312910910.1073/pnas.1203129109 ↗
34. 10.1038/srep1187810.1038/srep11878 ↗
35. 10.1021/acs.bioconjchem.5b0067410.1021/acs.bioconjchem.5b00674 ↗
36. 10.1186/s12951-018-0398-210.1186/s12951-018-0398-2 ↗
37. 10.1016/j.bbcan.2012.06.00310.1016/j.bbcan.2012.06.003 ↗
38. 10.1016/S0140-6736(18)32779-X10.1016/S0140-6736(18)32779-X ↗
39. 10.21037/atm.2018.05.1010.21037/atm.2018.05.10 ↗
40. 10.3389/fonc.2019.0008610.3389/fonc.2019.00086 ↗
41. 10.1093/jnci/djp07910.1093/jnci/djp079 ↗
42. 10.1097/CAD.0b013e328304355f10.1097/CAD.0b013e328304355f ↗
43. 10.1016/j.jconrel.2020.07.02210.1016/j.jconrel.2020.07.022 ↗
44. 10.1038/s41563-020-0755-z10.1038/s41563-020-0755-z ↗
45. 10.3390/CANCERS1407174110.3390/CANCERS14071741 ↗
46. 10.1016/j.copbio.2021.11.00610.1016/j.copbio.2021.11.006 ↗